Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Charles J.N. Lacey; Catherine Lowndes; Keerti V. Shah

doi:10.1016/j.vaccine.2006.06.015

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Charles J.N. Lacey^*, Catherine Lowndes, Keerti V. Shah

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

476 Citations (Scopus)

Abstract

Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.

Original language	English
Pages (from-to)	S35-S41
Journal	Vaccine
Volume	24
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1016/j.vaccine.2006.06.015
Publication status	Published - 21 Aug 2006

Keywords

HPV-6/11
Management
Non-cancerous

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2006.06.015

Cite this

@article{cd48a514823e4258aa5383baf7aa3ea6,

title = "Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease",

abstract = "Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.",

keywords = "HPV-6/11, Management, Non-cancerous",

author = "Lacey, {Charles J.N.} and Catherine Lowndes and Shah, {Keerti V.}",

year = "2006",

month = aug,

day = "21",

doi = "10.1016/j.vaccine.2006.06.015",

language = "English",

volume = "24",

pages = "S35--S41",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Chapter 4

T2 - Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

AU - Lacey, Charles J.N.

AU - Lowndes, Catherine

AU - Shah, Keerti V.

PY - 2006/8/21

Y1 - 2006/8/21

N2 - Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.

AB - Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.

KW - HPV-6/11

KW - Management

KW - Non-cancerous

UR - http://www.scopus.com/inward/record.url?scp=33747892746&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.06.015

DO - 10.1016/j.vaccine.2006.06.015

M3 - Article

C2 - 16950016

AN - SCOPUS:33747892746

SN - 0264-410X

VL - 24

SP - S35-S41

JO - Vaccine

JF - Vaccine

IS - SUPPL. 3

ER -

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this